Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibody
Pharma
InflaRx may find path forward for COVID drug in skin disorder
Positive post hoc analyses could prompt InflaRx to revive development of its COVID med vilobelimab in the rare skin disorder pyoderma gangrenosum.
Fraiser Kansteiner
Jan 2, 2026 10:25am
GSK scoops up yet another FDA approval, this time in asthma
Dec 17, 2025 8:30am
FDA signs off on Enflonsia, Merck's RSV shot for infants
Jun 9, 2025 4:33pm
InflaRx scraps vilobelimab study in rare skin disorder
May 28, 2025 9:55am
Invivyd's COVID prophylactic scores FDA emergency nod
Mar 25, 2024 11:59am
Roche's subcutaneous Ocrevus stacks up to original IV version
Oct 11, 2023 7:22am
